Capricor Shares Surge on Positive Phase 3 HOPE-3 DMD Trial Results
Introduction
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a clinical‐stage biotechnology company headquartered in San Diego, California. Founded in 2005, the firm focuses on developing cell‐ and exosome‐based therapies for serious diseases. Its lead candidate, deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy (DMD).
Corporate Structure
Capricor employs between 51 and 200 professionals across research, manufacturing, quality assurance, and program management. Its translational R&D model is supported by partnerships with academic institutions, leveraging expertise in cell biology, exosome engineering, and rare‐disease therapeutics. The company operates from a single campus at 10865 Road to the Cure, Suite 150, San Diego, CA 92121.
Biotechnology by Louis Reed
Recent Developments and News
- December 3, 2025: Capricor announced topline results from its pivotal Phase 3 HOPE-3 study of deramiocel in DMD, reporting that the trial met its primary cardiac endpoint and all Type 1 error–controlled secondary endpoints, maintaining a consistent safety profile. Management participated in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on the same day.
- November 10, 2025: The company released third-quarter financial results and a corporate update, highlighting ongoing progress across its cell and exosome programs.
- October 2025: Data detailing the mechanism of action and potency assay for deramiocel were published in the peer‐reviewed journal Biomedicines, outlining the anti-fibrotic and immunomodulatory effects of cardiosphere-derived cells.
- 2025 Recognition: Capricor was listed as #23 on TIME’s “America’s Growth Leaders 2026” list, indicating growth metrics among U.S. public companies.
Financial and Strategic Analysis
On December 3, 2025, CAPR shares closed at $22.17, reflecting a change of 248.58% on a trading volume of 11,916,768 shares. Key financial and operational metrics (trailing twelve months as of Q3 2025, end of September) include:
| Metric | Value |
|---|---|
| Stock Price (2025-12-03) | $22.17 |
| Market Capitalization (intraday) | $1.04 billion |
| Enterprise Value | $206.75 million |
| Revenue | $11.13 million |
| Net Loss | $81.99 million |
| EPS (TTM) | –$1.75 |
| Cash and Cash Equivalents | $98.57 million |
| Total Debt/Equity | 17.34% |
| Beta (5Y Monthly) | 0.59 |
The rise in stock price on December 3 corresponds with the announcement of HOPE-3 study results, which suggests that investor attention is focused on regulatory milestones. The company's cash position enables continued investment in R&D and upcoming regulatory filings for its exosome platform, which aims to facilitate the delivery of nucleic acids and proteins to target tissues.
Market Position and Industry Context
Capricor operates within the biotechnology research sector, specializing in cell and exosome therapies for rare diseases. In the DMD field, competitors include Sarepta Therapeutics and PTC Therapeutics, which focus on gene therapy and oligonucleotide strategies. Capricor differentiates itself through its allogeneic CDC technology and the development of exosome applications for drug delivery. The company's beta of 0.59 indicates lower volatility compared to the broader market, reflecting its specialized focus within the R&D landscape rather than extensive commercial operations.
tl;dr
On December 3, 2025, Capricor shares rose by 248.58% to $22.17 following the release of topline results from the Phase 3 HOPE-3 study of deramiocel in Duchenne muscular dystrophy. The trial successfully met primary and key secondary endpoints with a favorable safety profile. Management discussed these outcomes at the Piper Sandler Healthcare Conference. The company holds a cash balance of $98.57 million to support regulatory filings and the development of its exosome platform. Future catalysts include regulatory submissions for deramiocel and updates from exosome-based programs.